A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Clinical trial NCT02838420 · COMPLETED
Trial details
- NCT number
- NCT02838420
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-08-03
- Primary completion
- 2018-05-31
- Enrollment
- 187
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.